<DOC>
	<DOCNO>NCT01937507</DOCNO>
	<brief_summary>Deliver oxliplatin 5-FU via HAI breast cancer patient liver-only liver-predominant metastasis fail least one line systemic chemotherapy metastatic setting .</brief_summary>
	<brief_title>Hepatic Artery Infusion With FOLFOX Liver Metastasis From Breast Cancer</brief_title>
	<detailed_description>In pilot study , investigator deliver oxliplatin 5-FU via HAI breast cancer patient liver-only liver-predominant metastasis fail least one line systemic chemotherapy metastatic setting . The investigator hypothesize HAI chemotherapy able convert patient surgical resection candidate , or/and overcome chemo-resistance liver metastases systemic i.v . chemotherapy clinically fit , heavily pre-treated patient .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Performance status ECOG 02 life expectancy &gt; 3 month . 2 . Patients require measurable disease liver , define lesion measure &gt; 1 cm large diameter spiralcomputed tomography ( CT ) magnetic resonance imaging ( MRI ) 3 . Histologically confirm metastatic advance solid tumor involve liver , liver replacement le 70 % 4 . No bevacizumab ( avastin ) use within 4 week prior enrollment . 5 . Absence portal vein thrombosis 6 . Not surgical candidate patient refuge surgery time enrollment 7 . Loss response least 1 line systemic chemotherapy metastatic set 8 . An asymptomatic extrahepatic disease allow , provide extent metastatic disease liver represent bulk metastatic disease . 9 . History liverdirected therapy eligible investigator 's discretion . 10 . Adequate renal function calculate creatinine clearance great 60 mL/min . 11 . Hepatic function follow : Total Bilirubin ≤3 mg/dL , AST ≤5 time upper normal reference value , ALT ≤ 5 time upper normal reference value . 12 . Adequate bone marrow function ( ANC ≥1500 cells/uL ; PLT ≥ 100,000 cells/uL ) therapy . 13 . At least three week previous immunotherapy , chemotherapy radiotherapy enrol study . 14 . All female childbearing age MUST negative serum HCG test unless patient prior hysterectomy . 1 . Clinical radiographic evidence moderate amount ascites . 2 . History cirrhosis ChildPugh class B C. 3 . Pregnant lactating female . 4 . Inability complete inform consent process adhere protocol treatment plan followup requirement . 5 . Patients receive investigational agent . 6 . Patients bleed diathesis ( clinical bleeding , prothrombin time =/ &gt; 1.5 X upper institutional normal value , INR =/ &gt; 1.5 , activate partial thromboplastin time aPTT =/ &gt; 1.5 X upper institutional normal value ) , active gastric duodenal ulcer . 7 . History thrombophilia , recurrent DVTs , diagnosis phospholipid syndrome . 8 . Past current history malignancy breast cancer exception treat nonmelanoma skin cancer carcinoma situ cervix , cancer cure local therapy alone DFS ≥5 year . 9 . Concurrent severe illness active infection , psychiatric illness/social situation would limit safety compliance study requirement . 10 . Patients clinically significant cardiovascular disease : myocardial infarction unstable angina within 6 month , New York Heart Association Grade II great congestive heart failure , serious cardiac arrhythmia require medication , unstable angina pectoris , clinically significant peripheral vascular disease 11 . Patients untreated brain metastasis require leptomeningeal metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>